Abstracts tagged "Disease Activity"

Abstract Number: 0811 • ACR Convergence 2022
Reliability of CRP as an Inflammatory Marker in Patients with Immune Mediated Inflammatory Diseases (IMIDs) and Liver Dysfunction
Yael Ross¹ and Stanley Ballou², ¹Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, ²Case Western Reserve University - Metro Health, Cleveland, OH
Background/Purpose: C-reactive protein (CRP) is an acute-phase reactant widely employed clinically as a marker of inflammation. Serum CRP level is generally elevated with any type…
Abstract Number: 0996 • ACR Convergence 2022
Tapering of Corticosteroids or Immunosuppressive Therapy in Stable SLE: A Comparison of Complete Remission, Clinical Remission and Lupus Low Disease Activity State in Protection Against Flares
Jiacai Cho¹, liang shen², Molla Huq³, Rangi Kandane-Rathnayake⁴, Vera Golder⁴, Worawit Louthrenoo⁵, Yi-Hsin Chen⁶, Laniyati Hamijoyo⁷, Luo Shue Fen⁸, Yeong-Jian Wu⁸, Leonid Zamora⁹, Zhouli Zhang¹⁰, An Yuan¹¹, Sargunan Sockalingam¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Yanjie Hao³, Zhanguo Li¹⁴, Duminda Basnayake¹⁵, Madelynn Chan¹⁶, Jun Kikuchi¹⁷, Tsutomu Takeuchi¹⁸, Sang-Cheol Bae¹⁹, Fiona Goldblatt²⁰, Shereen Oon²¹, Sean O'Neill²², Kathy Gibson²², Kristine Ng²³, Hui Nee Annie Law²⁴, Nicole Tugnet²⁵, Sunil Kumar²⁶, Cherica Tee²⁷, Michael Tee²⁷, Naoaki Ohkubo²⁸, Yoshiya Tanaka²⁸, Sandra Navarra²⁹, Chak Sing³⁰, Alberta Hoi³¹, Eric Morand³², Mandana Nikpour³³ and Aisha Lateef³⁴, ¹National University Health System (NUHS), Singapore, Singapore, ²National University of Singapore, Singapore, Singapore, ³The University of Melbourne, Melbourne, Australia, ⁴Monash University, Clayton, Australia, ⁵Chiang Mai University, Chiang Mai, Thailand, ⁶Taichung Veterans General Hospital, Taichung, Taiwan, ⁷Hasan Sadikin Hospital, Jakarta Selatan, Indonesia, ⁸Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁹University of Santo Tomas Hospital, Manila, Philippines, ¹⁰Peking University First Hospital, Beijing, China, ¹¹Peking University Health Science Center, Beijing, China, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Division of Rheumatology, Department of Internal Medicine, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, ¹⁴People's Hospital, Peking University Health Science Center, Beijing, China, ¹⁵Teaching Hospital Kandy, Kandy, Sri Lanka, ¹⁶Tan Tock Seng Hospital, Singapore, Singapore, ¹⁷Keio University, Tokyo, Japan, ¹⁸Keio University and Saitama Medical University, Tokyo, Japan, ¹⁹Hanyang University Medical Center, Seoul, Republic of Korea, ²⁰Royal Adelaide Hospital and Flinders Medical Centre, Adelaide, Australia, ²¹St Vincent's Hospital, Fitzroy, Australia, ²²Liverpool Hospital, Sydney, Australia, ²³North Shore Hospital, Auckland, New Zealand, ²⁴Department of Rheumatology and Immunology, Singapore General Hospital, Singapore, Singapore, ²⁵Greenlane Clinical Centre, Auckland, New Zealand, ²⁶Middlemore Hospital, Auckland, New Zealand, ²⁷University of the Philippines, Quezon City, Philippines, ²⁸University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²⁹University of Santo Tomas, Manila, Philippines, ³⁰The University of Hong Kong, Pok Fu Lam, Hong Kong, ³¹Monash Health, Melbourne, Australia, ³²Monash University, Victoria; Department of Rheumatology, Monash Health, Melbourne, Australia, ³³The University of Melbourne at St. Vincent's Hospital Melbourne, Melbourne, Australia, ³⁴National University Hospital, Singapore, Singapore
Background/Purpose: Proposed targets of SLE treatment include lupus low disease activity state (LLDAS), clinical remission and complete remission. Whether treatment can be tapered after achieving…
Abstract Number: 1380 • ACR Convergence 2022
Development of Core and Expanded Datasets to Align Registries and Advance International Collaborative Research for Childhood-onset Systemic Lupus Erythematosus
Rebecca Sadun¹, Laura Lewandowski², Alexandre Belot³, Eve Smith⁴ and Jennifer Cooper⁵, ¹Duke University, Durham, NC, ²NIAMS, NIH, Bethesda, MD, ³Hospices Civils de Lyon, Collonges au mont d'or, France, ⁴University of Liverpool, Liverpool, United Kingdom, ⁵University of Colorado/Children's Hospital Colorado, Denver, CO
Background/Purpose: Childhood-onset systemic lupus erythematosus (cSLE) occurs in approximately 20% of all SLE cases. cSLE is has a worse prognosis than adult-onset SLE, often requiring…
Abstract Number: 1508 • ACR Convergence 2022
Enthesitis a Dominant Pathology in Psoriatic Arthritis: Identification and Quantification of Enthesitis Burden by 18F-FDG Total-Body PET/CT Imaging
Siba Raychaudhuri¹, Yasser Abdelhafez², Dario Mazza³, Smriti Raychaudhuri⁴ and Abhijit Chaudhari³, ¹UC Davis, School of Medicine/ VA Medical Center, Sacramento, CA, ²University of California Davis, Sacramento, CA, ³UC Davis, School of Medicine, Sacramento, CA, ⁴VA Medical Center, Sacramento, CA
Background/Purpose: The enthesitis can be the earliest/primary inflammatory event in psoriatic arthritis (PsA). Clinically most of the entheses are not accessible and can't be assessed;…
Abstract Number: 1833 • ACR Convergence 2022
Intraarticular Morphine in Knee-arthritis – Results of a Randomized Placebo-controlled Trial
Hildrun Haibel¹, Joachim Sieper¹, Denis Poddubnyy², valeria Rios-Rodriguez³, Fabian Proft², Mikhail Protopopov⁴, Judith Rademacher⁴, Sabrina Igel⁵, Peter Martus⁶ and Christoph Stein⁵, ¹Charité - Universitätsmedizin, Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ³Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany, ⁶University Hospital Tübingen, Tübingen, Germany
Background/Purpose: The current standard of intraarticular therapy in patients with inflammatory arthritis (e.g. rheumatoid arthritis; RA) or inflammatory exacerbations of osteoarthritis (OA) is the injection…
Abstract Number: 2090 • ACR Convergence 2022
Evaluation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) vs. SLEDAI-2K Glucocorticoids (SLEDAI-2KG) on Patient Health-Related Quality of Life (HRQoL) in Systemic Lupus Erythematosus (SLE)
Alan Cheng¹, Vibeke Strand², Jiandong Su³, Nicole Anderson³, Lee S Simon⁴ and Zahi Touma³, ¹Michael G. DeGroote School of Medicine, McMaster University, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Stanford University School of Medicine, Stanford, CA, ³Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ⁴SDG LLC, West Newton, MA
Background/Purpose: Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K) Glucocorticoid Index (SLEDAI-2KG) is a novel valid index able to measure disease activity while accounting for prednisone…
Abstract Number: 0016 • ACR Convergence 2022
Distinct Transcriptomic and Epigenetic Profiles Mediated by Disease Activity in SLE
Yusho Ishii, James Rose, Kevin Cashman, Sakeenah Hicks, Tsuneo Deguchi, Christopher Scharer, Scott Jenks, Jeremy Boss and Iñaki Sanz, Emory University, Atlanta, GA
Background/Purpose: SLE is an autoimmune disease heterogenous for symptoms, disease severity and therapeutic response. This heterogeneity makes stratifying patients difficult. B cells from SLE patients…
Abstract Number: 0393 • ACR Convergence 2022
Are We Meeting Patients’ Treatment Goals with Guideline-Based Therapy for Psoriatic Arthritis?
Christeen Samuel¹, Laura Prichett¹, Thomas Grader-Beck¹, Uzma Haque¹, John Miller¹, Suzanne Grieb² and Ana-Maria Orbai³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University School of Medicine and School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD
Background/Purpose: Treatment success from the patients' perspective has not been defined in psoriatic arthritis (PsA). The objective was to determine prevalence and associations of patient-reported…
Abstract Number: 0850 • ACR Convergence 2022
Outcomes of Patients with Juvenile Idiopathic Arthritis Following Failure of Initial Tumor Necrosis Factor Inhibitor Medication in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Shahla Amin², Stephen Balevic³, Colleen Correll⁴, Timothy Beukelman¹ and , for the CARRA Registry Investigators⁵, ¹University of Alabama at Birmingham, Birmingham, AL, ²Childhood Arthritis and Rheumatology Research Alliance, Washington, DC, ³Duke University, Durham, NC, ⁴University of Minnesota, Minneapolis, MN, ⁵CARRA, Washington, DC
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are the most commonly used first biologics to treat juvenile idiopathic arthritis (JIA), but it is unknown what subsequent…
Abstract Number: 1023 • ACR Convergence 2022
Are We Treating-to-target in Spondyloarthritis (SpA)? A Cross Sectional Analysis from the Asia Pacific League of Associations for Rheumatology (APLAR) SpA Registry
Isaac Cheng¹, Ying Ying Leung², Ho SO¹, Praveena Chiowchanwisawakit³, Stanley Angkodjojo⁴, Muhammad Saeed⁵, Kichul Shin⁶, Han Joo Baek⁷, Mohit Goyal⁸, Muhammad Haroon⁹, Eman Satti¹⁰, Nallasivan Subramanian¹¹, Fariz Yahya¹², Soosan Soroosh¹³, ASAL ADNAN RIDHA¹⁴, Ho Yin Chung¹⁵, James Cheng-Chung WEI¹⁶, Kishimoto Mitsumasa¹⁷ and Lai-shan Tam¹, ¹The Chinese University of Hong Kong, Hong Kong, China, ²Rheumatology Department, Singapore General Hospital, Singapore, Singapore, ³Mahidol University, Bangkok, Thailand, ⁴Sengkang General Hospital / Singhealth, Singapore, Singapore, ⁵Central Park Medical College, Lahore, Pakistan, ⁶Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ⁷Gachon University College of Medicine, Inchon, Republic of Korea, ⁸CARE Pain & Arthritis Centre, Udaipur, India, ⁹Doctor, Tralee, Ireland, ¹⁰Hamad Medical Corporation, Doha, Qatar, ¹¹Velammal Medical College Hospital, Velammal, India, ¹²University of Malaya, Kuala Lumpur, Malaysia, ¹³Army University for Medical School, Tehran, Iran, ¹⁴Baghdad Teaching Hospital, Baghdad, Iraq, ¹⁵Chiron Medical, Hong Kong, Hong Kong, ¹⁶Chung Shan Medical University Hospital, Taichung, Taiwan, ¹⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Data on the extent to which internationally agreed treat-to-target (T2T) recommendations were applied in clinical practice in patients with SpA across the Asia-Pacific region…
Abstract Number: 1390 • ACR Convergence 2022
Distinct Patterns of Multimorbidity Are Associated with Longitudinal Disease Activity and Functional Status in a Multicenter, Prospective Rheumatoid Arthritis Cohort
Sarah Dutt¹, Punyasha Roul², Yangyuna Yang³, Kaleb Michaud³, Brian Sauer⁴, Grant Cannon⁵, Joshua Baker⁶, Jeffrey Curtis⁷, Ted Mikuls⁸ and Bryant England³, ¹University of Nebraska Medical Center, Omaha, ²UNMC, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁵Salt Lake City VA, Salt Lake city, ⁶University of Pennsylvania and Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Rheumatoid arthritis (RA) predisposes to the development of other chronic conditions such as osteoporosis, cardiovascular disease, and lung disease. Previously, we used unsupervised machine…
Abstract Number: 1515 • ACR Convergence 2022
Assessing the Difference Between Radiographic Axial Spondylorthritis and Non-radiographic Axial Spondylorthritis in a Two-center Descriptive Study with Mexican Patients: The Influence of Clinical, Demographic, Laboratory and Clinimetric Features
John Londono¹, Gustavo Rodriguez-Salas², Igor Rueda-Cardenas³, Ana Maria Santos¹, Marta Mantilla¹, Juan Camilo Santacruz², Cesar Pachecho⁴, Gilberto Vargas-Alarcon⁵ and Ruben Burgos vargas⁶, ¹Spondyloarthropathies study group - Universidad de La Sabana - Hospital Militar Central, Bogotá, Colombia, ²Spondyloathropathies study group Universidad de La Sabana Hospital Militar Central, Bogotá, Colombia, ³Spondyloarthropathies study group - Universidad de LA Sabana - Hospital Militar Central, Colombia, Colombia, ⁴Universidad Autónoma de chihuahua, Chihuahua, Mexico, ⁵Insituto Nacional de Cardiología Ignacio Chavez, Ciudad de México, Mexico, ⁶hospital general de mexico, Ciudad de México, Mexico
Background/Purpose: Spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases that have some key features in common. According to ASAS, this condition is classified into…
Abstract Number: 1877 • ACR Convergence 2022
Nailfold Videocapillaroscopic Abnormalities Correlate with Disease Activity Measures and Cutaneous Damage in Patients with Idiopathic Inflammatory Myopathies
Diane Zisa¹, Aliza Bloostein¹, Deanna Jannat-Khah, DrPH, MSPH¹, Maurizio Cutolo², Vanessa Smith³ and David Fernandez¹, ¹Hospital for Special Surgery, New York, NY, ²Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genova, Italy, ³Department of Rheumatology, Ghent University Hospital – Department of Internal Medicine, Ghent University, Belgium – Unit for Molecular Immunology and Inflammation, VIB Inflammation Research Center (IRC), Gent, Belgium
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a non-invasive tool used to evaluate the microcirculation of patients with connective tissue diseases (CTDs). A specific combination of NVC…
Abstract Number: 2095 • ACR Convergence 2022
Validation Analysis of the Physician Global Assessment (PGA) Scale in Patients with Systemic Lupus Erythematosus Included in RELESSER-PROS Registry
Laura Cáceres¹, Iñigo Rúa-Figueroa¹, Norman Jimenez², María Galindo-Izquierdo³, Jaime Calvo⁴, Raul Menor Almagro⁵, Antonio Fernandez-Nebro⁶, Julia Martinez-Barrio⁷, Esther Rodriguez Almaraz³, Esther Uriarte Isacelaya⁸, Elena Aurrecoechea⁹, Natalia Mena Vazquez⁶, José Miguel Senabre¹⁰, José Antonio Bernal¹¹, Ana Pérez¹², Vicente Torrente¹³, F. Javier Narváez¹⁴, Clara Sangüesa¹⁵, Marta Arévalo¹⁶, Mercedes Freire¹⁷, Clara Moriano¹⁸, Carlota Iñiguez¹⁹, Eva Tomero Muriel²⁰, José Luis Andreu²¹, Mª Jesús García²², Tatiana Cobo²³, Gema Bonilla²⁴, Nuria Lozano²⁵, Loreto Horcada²⁶, Carlos Montilla²⁷, Lorena Expósito²⁸, María Esther Ruiz²⁹, José Eloy Oller³⁰, Ángela Pecondón³¹, Javier Loricera³², Francisco Javier Novoa³³, Eva Salgado³⁴, Tarek Carlos Salman-Monte³⁵, Alejandro Muñoz³⁶, Jorge J Fragío Gil³⁷ and Jose M Pego-Reigosa³⁸, ¹Hospital Universitario Dr Negrín, Las Palmas de Gran Canaria, Spain, ²IRIDIS Group, Vigo, Spain, ³Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario de Araba, Vitoria, Spain, ⁵Hospital Jerez de la Frontera, Cádiz, Spain, ⁶Regional University Hospital of Málaga, Málaga, Spain, ⁷Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁸Hospital Universitario Donostia, Donostia, Spain, ⁹Hospital de Sierrallana, Torrelavega, Spain, ¹⁰Hospital Marina Baixa, Villajoyosa, Spain, ¹¹Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ¹²University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain, ¹³Hospital de Sant Joan Despí Moisès Broggi/Consorci Sanitari Integral (CSI), Sant Joan Despí, Spain, ¹⁴Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵Hospital Universitario Severo Ochoa, Madrid, Spain, ¹⁶Parc Tauli Hospital Universitari, Sabadell, Catalonia, Spain, ¹⁷Complejo H. Universitario de A Coruña, A Coruña, Spain, ¹⁸Complejo Asistencial Universitario de León, León, Spain, ¹⁹Hospital Universitario Lucus Augusti, Division of Rheumatology, Lugo, Spain, ²⁰Hospital Universitario La Princesa, Madrid, Spain, ²¹Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ²²Hospital Universitario Ramón y Cajal, Madrid, Spain, ²³Hospital Infanta Sofía, San Sebastián de los Reyes, Spain, ²⁴Hospital Universitario La Paz, Madrid, Spain, ²⁵Hospital Virgen de la Arrixaca, Murcia, Spain, ²⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ²⁷Complejo asistencial Universitario de Salamanca, Salamanca, Spain, ²⁸Hospital Universitario de Canarias, La Laguna, Spain, ²⁹Hospital Universitario de Basurto, Bilbao, Spain, ³⁰Hospital Universitario Dr. Peset, València, Spain, ³¹Hospital Universitario Miguel Servet, Zaragoza, Spain, ³²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³³Complejo Hospitalario Universitario Insular de Gran Canarias, Las Palmas de Gran Canaria, Spain, ³⁴Complejo Hospitalario De Orense, Ourense, Spain, ³⁵Hospital del Mar/Parc de Salut Mar-IMIM/UEC-AIS, Barcelona, Spain, ³⁶Hospital Universitario Virgen del Rocío, Sevilla, Spain, ³⁷Rheumatology Department. Hospital Universitario y Politécnico La Fe, València, Comunidad Valenciana, Spain, ³⁸Hospital Meixoeiro, Vigo, Spain
Background/Purpose: There is currently no agreement on which scale should be used to evaluate SLE disease activity. The aim of this study was to analyze…
Abstract Number: 0098 • ACR Convergence 2022
Delays in Access to Specialized Care and Diagnosis in Patients with Systemic Lupus Erythematosus
Alain Sanchez-Rodriguez¹, Jose A Meade-Aguilar², Jeffrey X. Yang², Gabriel Figueroa Parra², Shirley-Ann Osei-Onomah², Rachel Giblon³, Hannah Langenfeld⁴, Alanna Chamberlain², Cynthia Crowson⁵ and Ali Duarte-Garcia², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN, Rochester, MN, ⁴Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ⁵Mayo Clinic, Eyota, MN
Background/Purpose: Delays in access to specialized care and diagnosis of systemic lupus erythematosus (SLE) are associated with poor outcomes. Prior studies rely mostly on cross-sectional…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].